Court Says FibroGen’s UK Roxadustat Patents Are Invalid
Ruling Favors Akebia/Otsuka’s Rival Anemia Drug
Executive Summary
A complex and weighty judgment from the High Court regarding a new class of anemia compounds tackles a range of thorny patent law issues including obviousness, insufficiency and indirect infringement.
You may also be interested in...
Vadadustat Emerges As Japan HIF-PHI Contender With First Filing Globally
Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.
UK Confirms It Will Accept EU Marketing Authorizations For Two Years
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
Brexit: Life Science Firms In An ‘Impossible Position’
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: